Invesco Ltd. Raises Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Invesco Ltd. increased its stake in Kiniksa Pharmaceuticals by 137.4% during the first quarter, bringing its total ownership to 33,492 shares valued at $744,000.
• Other institutional investors, including Millennium Management LLC and Deutsche Bank AG, also significantly raised their positions in Kiniksa, reflecting growing institutional interest in the biotech firm.
• Despite a recent downgrade to a "buy" rating by Wall Street Zen, analysts maintain a consensus rating of "Buy" for Kiniksa Pharmaceuticals, with an average target price of $41.17.

Invesco Ltd. raised its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 137.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,492 shares of the company's stock after buying an additional 19,384 shares during the period. Invesco Ltd.'s holdings in Kiniksa Pharmaceuticals International were worth $744,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after purchasing an additional 54,361 shares in the last quarter. Millennium Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 50.9% during the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after purchasing an additional 263,146 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Kiniksa Pharmaceuticals International by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares in the last quarter. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 1.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock valued at $15,141,000 after purchasing an additional 10,209 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Finally, Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $41.17.

Insider Buying and Selling

In other news, CAO Michael R. Megna sold 11,000 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total value of $383,240.00. Following the sale, the chief accounting officer owned 38,011 shares of the company's stock, valued at $1,324,303.24. The trade was a 22.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eben Tessari sold 13,389 shares of the business's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $35.66, for a total transaction of $477,451.74. Following the transaction, the chief operating officer directly owned 44,452 shares of the company's stock, valued at approximately $1,585,158.32. This represents a 23.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 619,649 shares of company stock valued at $20,465,432. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock traded down $0.60 on Tuesday, reaching $35.98. 35,560 shares of the company traded hands, compared to its average volume of 667,368. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $36.74. The company has a 50 day moving average of $31.13 and a 200 day moving average of $26.70. The firm has a market capitalization of $2.67 billion, a PE ratio of 901.35 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.